Point Biopharma Global Inc Reports Results For The Quarter Ended In September: Earnings Summary

POINT Biopharma Global

14/11/2022 16:33

* POINT Biopharma Global Inc  PNT.OQ  reported a quarterly
adjusted loss of 26 cents​​ per share for the quarter ended in
September. The mean expectation of nine analysts for the quarter
was for a loss of 28 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * POINT Biopharma Global Inc's reported EPS for the quarter
was a
loss of 26 cents​.
    * The mean earnings estimate of analysts had risen by
about 4% in
the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * POINT Biopharma Global Inc shares had risen by 18.2% this
quarter and gained 63.2% so far this year.
    * The company reported a quarterly loss of $24.01 million.
    * Wall Street's median 12-month price target for POINT
Biopharma
Global Inc is $21.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 04:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.28          -0.26          Beat
 Jun. 30 2022      -0.22          -0.27          Missed
 Mar. 31 2022      -0.21          -0.18          Beat
 Dec. 31 2021      -0.23          -0.16          Beat